Callan Family Office LLC Grows Position in Agilent Technologies, Inc. $A

Key Points

• Callan Family Office LLC increased its position in Agilent Technologies by 75%, now holding 13,962 shares valued at $1.648 million.
• A number of brokerages have raised their price targets for Agilent Technologies, with JPMorgan Chase increasing it from $155 to $165 and maintaining an "overweight" rating.
• Agilent Technologies recently announced a quarterly dividend of $0.248 per share, reflecting an annualized yield of 0.7% and a payout ratio of 23.24%.

Callan Family Office LLC grew its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 75.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,962 shares of the medical research company's stock after buying an additional 5,984 shares during the period. Callan Family Office LLC's holdings in Agilent Technologies were worth $1,648,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in A. Brighton Jones LLC grew its position in shares of Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock valued at $626,000 after purchasing an additional 270 shares during the period. GAMMA Investing LLC grew its position in shares of Agilent Technologies by 34.6% in the first quarter. GAMMA Investing LLC now owns 5,362 shares of the medical research company's stock valued at $627,000 after purchasing an additional 1,379 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Agilent Technologies by 8.3% in the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after purchasing an additional 2,371 shares during the period. New England Research & Management Inc. purchased a new stake in shares of Agilent Technologies in the first quarter valued at $1,664,000. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Agilent Technologies by 86.3% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 51,363 shares of the medical research company's stock valued at $6,009,000 after purchasing an additional 23,800 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on A. JPMorgan Chase & Co. lifted their price objective on Agilent Technologies from $155.00 to $165.00 and gave the company an "overweight" rating in a research report on Thursday. Wall Street Zen raised Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Friday, October 3rd. Robert W. Baird lifted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Wells Fargo & Company lifted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Monday, September 15th. Finally, Barclays lifted their target price on Agilent Technologies from $125.00 to $150.00 and gave the company an "equal weight" rating in a report on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Agilent Technologies has an average rating of "Moderate Buy" and a consensus price target of $148.69.

Agilent Technologies Trading Down 2.5%

Shares of A opened at $136.62 on Friday. The stock's 50-day moving average is $125.04 and its two-hundred day moving average is $117.03. The stock has a market cap of $38.73 billion, a PE ratio of 32.07, a P/E/G ratio of 4.46 and a beta of 1.26. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts' consensus estimates of $1.37. The company had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm's quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Tuesday, September 30th. Agilent Technologies's payout ratio is currently 23.24%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.